Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749892 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00749892: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00749892 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 34 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00749892, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Interventions
- DRUG Erlotinib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2008-06-10 |
| Est. Completion | 2019-11-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749892
The ClinicalTrials.gov registry entry for NCT00749892 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erlotinib Hydrochloride is the first listed.
NCT00749892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00749892 about?
NCT00749892 is a clinical study titled "Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer". This phase II trial studies how well erlotinib hydrochloride works in Treating participants with muscle invasive urothelial cancer or urothelial cancer that has come back. Drugs used in chemotherapy, such as erlotinib hydrochloride, work in different ways to stop the growth of tumor cells, either by...
What is the current status of trial NCT00749892?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2008-06-10. Estimated completion is 2019-11-26.
What interventions are being tested in trial NCT00749892?
The interventions under investigation include: Erlotinib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00749892?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.